Du JY, Zhang CT, Li T, Li YP. Targeting hypoxia and angiogenesis in hepatocellular carcinoma: New insights and therapeutic strategies. World J Hepatol 2024; 16(12): 1371-1376 [PMID: 39744195 DOI: 10.4254/wjh.v16.i12.1371]
Corresponding Author of This Article
Ya-Ping Li, MD, PhD, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 West 5th Road, Xincheng District, Xi’an 710004, Shaanxi Province, China. liyaping8605@xjtu.edu.cn
Research Domain of This Article
Agriculture, Dairy & Animal Science
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Du JY, Zhang CT, Li T, Li YP. Targeting hypoxia and angiogenesis in hepatocellular carcinoma: New insights and therapeutic strategies. World J Hepatol 2024; 16(12): 1371-1376 [PMID: 39744195 DOI: 10.4254/wjh.v16.i12.1371]
World J Hepatol. Dec 27, 2024; 16(12): 1371-1376 Published online Dec 27, 2024. doi: 10.4254/wjh.v16.i12.1371
Targeting hypoxia and angiogenesis in hepatocellular carcinoma: New insights and therapeutic strategies
Jia-Yi Du, Chu-Ting Zhang, Ting Li, Ya-Ping Li
Jia-Yi Du, Laboratory of Epidemiology and Public Health, Yale University School of Public Health, New Haven, CT 06510, United States
Chu-Ting Zhang, Ting Li, Ya-Ping Li, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Author contributions: Du JY and Li YP wrote the original manuscript; Du JY, Li T, and Li YP contributed to the conceptualization of the manuscript; Du JY, Zhang CT, and Li T contributed to the methodology design and software application; Zhang CT validated the manuscript as well as formally analyzed the article; Li YP supervised the article, and project managed it; Li YP and Zhang CT reviewed and edited the article.
Supported by the Basic and Clinical Integration Project of Xi’an Jiaotong University, No. YXJLRH2022067.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Ping Li, MD, PhD, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 West 5th Road, Xincheng District, Xi’an 710004, Shaanxi Province, China. liyaping8605@xjtu.edu.cn
Received: September 19, 2024 Revised: October 15, 2024 Accepted: October 29, 2024 Published online: December 27, 2024 Processing time: 74 Days and 3.5 Hours
Abstract
In this manuscript we comment on the article by Yang et al published recently, focusing on how hepatic angiopoietin-2 (Ang-2) transcription promote the progression of hepatocellular carcinoma (HCC). HCC is one of the most common and lethal malignancies worldwide, especially in regions with high hepatitis B virus infection rates. Ang-2 is a key mediator of angiogenesis and plays a significant role in the progression of chronic liver diseases towards HCC, particularly in the hypoxic microenvironment. This paper reviews the dynamic expression of Ang-2 in hepatocarcinogenesis and its regulation by hypoxia-inducible factor-1α. Furthermore, we discuss Ang-2’s potential as an early monitoring biomarker for metastasis, and the therapeutic prospects of silencing hypoxia-inducible factor-1α to downregulate Ang-2 and suppress epithelial-mesenchymal transition in HCC treatment.
Core Tip: In hepatocellular carcinoma (HCC) progression, hypoxia-inducible factor-1α (HIF-1α) promotes tumor angiogenesis, invasion, and metastasis by upregulating angiopoietin-2 (Ang-2), particularly within the hypoxic microenvironment. The synergistic interaction between HIF-1α and Ang-2 not only facilitates tumor cell epithelial-mesenchymal transition but may also contribute to multidrug resistance. Therefore, targeting the HIF-1α/Ang-2 axis holds promise as a therapeutic strategy to inhibit HCC metastasis and improve patient prognosis. Moreover, Ang-2 may serve as a potential biomarker for early HCC diagnosis and progression monitoring.
